Market Overview

Soliton Rallies On FDA Approval For Tattoo Removal Device

Share:
Soliton Rallies On FDA Approval For Tattoo Removal Device

Medical device company Soliton Inc. (NASDAQ: SOLY) has received FDA 510(k) approval for its acoustic wave device for dermal tattoo clearing.

Soliton shares were ripping higher by 130.37 percent at $13.20 at the time of publication Tuesday. 

What Happened 

Soliton has developed a breakthrough science for tattoo removal using rapid acoustic pulse, or RAP, technology. The FDA approved the RAP tattoo removal device, and the application will now move to a substantive review.

The device is indicated as an accessory to the 1064 nm Q-Switched (pulsed) laser for black ink tattoo removal on the arms, legs and torso in Fitzpatrick skin type I-III individuals, according to Soliton. 

Why It's Important 

Clinical trials have demonstrated that using the company's RAP device in conjunction with a Q-Switched laser allows for multiple passes of laser treatment in a single treatment session.

In clinical trials using the RAP device in conjunction with a Q-Switched laser, patients experienced 75-100-percent removal of their tattoos in just three office visits, the company said. 

"Having found that our submission contained all the necessary elements and information, we look forward to the substantive review and FDA clearance of the RAP device," Soliton CEO Christopher Capelli said in a statement. 

The tattoo removal market is estimated to be approximately $4.8 billion in size by 2023, Capelli said. 

"Because our technology relies upon replaceable cartridges for each treatment, we believe our business model will benefit from recurring revenue, allowing Soliton to share in the volume growth in the aesthetic category expected in the coming years."

Related Links:

Soliton Responds To Blog Calling It A 'PR Machine'

Mid-Day Market Update: Anaplan Jumps Following Upbeat Q1 Results; Kezar Life Sciences Shares Slide

Posted-In: News FDA Best of Benzinga

 

Related Articles (SOLY)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Citron Doubles Down on Jumia Short Thesis

Micro-Cap Biotech Kezar Life Sciences Trades Sharply Lower On New Data